Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon
Shockwave Medical, a Johnson & Johnson MedTech company, has officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Shockwave’s E8 catheter was designed specifically to treat patients with calcified femoropopliteal and below-the-knee (BTK) peripheral artery disease (PAD), including those diagnosed with complex chronic limb-threatening ischemia (CLTI).

Shockwave Medical launches new FDA-approved IVL catheter for PAD, CLTI

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD. 

SpectraWAVE, a Massachusetts-based imaging company focused on treatments for patients with coronary artery disease (CAD), has closed a $50 million funding round. Johnson & Johnson Innovation led the round, and other participants included S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture and Heartwork Capital.

SpectraWAVE raises $50M for FDA-cleared intravascular imaging technology

The funds, including a significant investment from Johnson & Johnson, are expected to go toward expanding access to the company's HyperVue Imaging System and exploring new features.

Implantable Barostim device improves long-term heart failure symptoms

The FDA-approved device helps regulate the heart, kidneys and vascular system by targeting sensors in a patient's carotid artery. 

cross market hospital mergers

Abiomed, Biosense Webster, Cerenovus now all known as Johnson & Johnson MedTech

These companies were already part of the Johnson & Johnson family, but they had still retained their previous brand names. Now, each one is officially going by Johnson & Johnson MedTech. 

Map of Congressional districts and the rate of amputations based on medicare data showing Mississippi delta region with the highest number of amputation procedures per year. Dr. Fakorede located his practice there to try and combat extremely the high PAD and CLI rates.

PAD is a public health crisis say cardiovascular societies

September is peripheral artery disease (PAD) awareness month, and medical societies are using it to promote awareness for patients and referring physicians to act against the debilitating disease.
 

Thumbnail

‘An excellent outcome’: TAVR safe and effective for patients in their nineties

Bleeding and vascular complications were more common, but one-year outcomes confirmed patients in their nineties should still be considered for TAVR.

Pausing oral anticoagulation during TAVR reduces bleeding risk

The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.

OCT-guided PCI, or optical coherence tomography-guided percutaneous coronary intervention.

OCT-guided PCI boosts outcomes when treating complex lesions

When PCI patients present with complex lesions, optical coherence tomography may provide significant value.

Displaying 17 - 24 of 1638

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.